Our work is in the understanding of how cancer genomes affect drug sensitivity and resistance. To this end we use state-of-the-art informatics, next-generation sequencing technologies and genetic screens.
Ultimately our goal is to create knowledge of what drives drug response and resistance in cancer that will be of benefit to patients.
Key areas of reseach focus in my laboratory are:
- Genome-wide genetic screens (CRISPR/Cas9, CRISPRa and chemical mutagenesis) to systematically identify genes involved in the evolution of drug resistance in cancer, both to targeted agents, chemotherapeutics and radiotherapy
- Genetic screens (RNAi and CRISPR/Cas9) to identify novel vulnerabilities in cancer cells that may be tomorrow's drug targets
- Next-generation sequencing of metastatic and recurrent tumour samples to identify patterns of evolution that faciliatate these processes
To find out more indepth information please click on the read more button below.